Behavioral and Cardiopulmonary Effects of a Constant Rate Infusion of Remifentanil-Xylazine for Sedation in Horses

Total intravenous anesthesia with propofol-ketamine-xylazine with or without remifentanil in thoroughbred horses undergoing castration

We evaluated the clinical efficacy of total intravenous anesthesia (TIVA) with propofol-ketamine-xylazine (PKX) with or without remifentanil for castration in horses. Twenty-four Thoroughbred horses were premedicated with intravenous (IV) xylazine (1.0 mg/kg) and midazolam (0.02 mg/kg) and anesthetized with IV ketamine (1.5 mg/kg) and propofol (1.0 mg/kg). Surgical anesthesia was maintained with constant infusion of propofol (3.0 mg/kg/hr)-ketamine (3.0 mg/kg/hr)-xylazine (1.0 mg/kg/hr) (group PKX: n=8), PKX combined with remifentanil (3.0 µg/kg/hr) (group PKXR3: n=8), or PKX combined with remifentanil (6.0 µg/kg/hr) (group PKXR6: n=8). During anesthesia, none of the horses showed any limb movements, but five, two, and two horses in the PKX, PKXR3, and PKXR6 groups, respectively, showed cremaster muscle contractions. One horse in the PKX group required doubling the PKX infusion rate to continue surgery. Adverse effects of remifentanil (trembling of the nose tip or tongue) were observed in one and three horses in the PKXR3 and PKXR6 groups, respectively. Heart rate and arterial blood pressure were well maintained in all groups. Ventilation was assisted in four, five, and six horses in the PKX, PKXR3, and PKXR6 groups, respectively. Recovery scores in the PKX group were fair in one horse, good in three horses, and excellent in four horses, whereas recovery in all horses in the PKXR3 and PKXR6 groups was judged to be excellent. TIVA with PKX combined with remifentanil 3.0 µg/kg/hr could provide more sufficient anesthetic depth than PKX with fewer clinically significant adverse effects than that with remifentanil 6.0 µg/kg/hr.

Accelerometric Evaluation of the Locomotor Pattern After Administration of Morphine in Conscious Healthy Horses

The objective of the present study was to compare, using accelerometry, the gait changes produced after administration of a dose of 0.2 mg/kg of morphine at the walk in healthy horses. Six mature horses were used, and all animals received two different treatments with, at least, two weeks interval in between. Treatments administered consisted of a single dose of 10 ml of saline solution or a total of 0.2 mg/kg of morphine diluted in 10 ml of saline solution. A three-dimensional accelerometric device was used to collect data continuously while horses were walking. The walking test was performed 10 min prior to injection, and then at 5, 10, 15 and 20 min after injection and then every 10 min for 3 h. Eight variables were calculated including stride kinematic, coordination and energetic parameters. Additionally, the force of acceleration and three components of the power were calculated. Significant interaction was only observed for stride length, propulsion power and the propulsive part of the total power with a reduction in values after morphine administration. Compared to baseline values, stride length values were significantly reduced for 80 min and again 110 min after injection of the opioid and at 5, 15, 20, 30 and 40 min in the case of propulsion power values. For the propulsion component of power, these differences were observed for 20 min when compared to baseline values. The administration of 0.2 mg/kg of morphine to conscious healthy horses produces limited effects on the gait pattern of horses and the effects on locomotor activity are minimal at this dose, not being an important concern for the administration of analgesia in a clinical setting.